JAYPIRCA DIN 02562014
Health Canada record
| Active ingredient(s) | PIRTOBRUTINIB 100 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01EL05 PIRTOBRUTINIB |
| Original market date | 28-Nov-2025 |
| Current status date | 28-Nov-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Eli Lilly Canada Inc. — licence 100164, currently licensed, last inspection rating C (2026-03-24).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing PIRTOBRUTINIB
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02562006 | JAYPIRCA | ELI LILLY CANADA INC | Tablet | PIRTOBRUTINIB 50 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36204 | 2025-10-17 | New Drug Submission (NDS) |
International API supply for PIRTOBRUTINIB
3 active FDA Drug Master Files.
Special Access Programme
This molecule appears on Health Canada's list of drugs most often requested through the Special Access Programme.
Request a quote for JAYPIRCA